Board of directors

Martin_100x100_2014.jpg

Martin Nicklasson

Chairman of the Board
Chairman of the Remuneration and
Compensation Committee
Chairman of the Nomination Committee
Elected to the Board in 2015 and regarded as an independent board member.

 

Qualifications
Certified pharmacist.
Ph.D. in Pharmaceutical Technology from the University of Uppsala, where he is an Associate Professor in the Department of Pharmaceutics.

Competencies
Martin Nicklasson has held various Executive Vice President positions at AstraZeneca plc and has served as President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB (publ). Prior to this, he held a number of leadership positions at Astra and Kabi Pharmacia. Martin Nicklasson is chairman of the board of Orexo AB and Kymab Group Ltd.. He serves as a board member of Basilea Pharmaceutica Ltd. andBioCrine AB, . He previously served as a board member of Scandinavian Life science invest AB, Denator AB, Pozen Inc., Oasmia AB, Farma Investment AS, PledPharma AB, BioInvent International AB, Premier Research Group Ltd. and EffRx Pharmaceuticals SA within the past five years.


ZP150521_036_SH_back_100x100.jpg

Rosemary Crane

Vice Chairman of the Board
Elected to the Board in 2015 and
regarded as an independent board member.

Qualifications
BA in Communication from the State University of New York and MBA from Kent State University.

Competencies
Rosemary Crane has been CEO of Mela Sciences and Epocrates, and has held a
number of leading positions at Johnson & Johnson and BMS. Rosemary Crane is a member of the boards of Teva Pharmaceutical Industries Ltd. and Cipher Pharmaceuticals Inc. and a member of the advisory boards of the State University of New York at Oswego School of Business and the foundation board of the State University of New York at Oswego.


Catherine_100x100_2014.jpg

Catherine Moukheibir

Board member
Chairman of the Audit Committee
Elected to the Board in 2015 and regarded as an independent board member.

Qualifications
MA in economics and a MBA from Yale University.

Competencies
After a career in strategy consulting and investment banking in Boston and
London, Catherine Moukheibir has held senior management positions in
several European biotech companies.

Catherine Moukheibir is Chairman of the Board of MedDay Pharmaceuticals S.A.
and a board member of Ablynx S.A. and Cerenis Therapeutics Holding S.A. She is
also a member of the Advisory Board at Imperial College Business School, UK.


Alain_Munoz_100x100.jpg

Alain Munoz

Board member
Elected to the Board in 2005 (resigned in 2006, was re-elected in 2007) and regarded as an independent board member.

Qualifications
MD in Cardiology and Anaesthesiology,
head of clinical department of cardiology
at the University Hospital of Montpellier. He has numerous publications and
has been a member of the scientific committee of the French Drug Agency.

Competencies
Alain Munoz is the owner and CEO of Science, Business and Management SARL (France), and has over 25 years' experience in the pharmaceutical industry at senior management level. He served as SVP for International development within the Sanofi Group and as SVP for the Pharmaceutical division in Fournier Laboratories.

Alain Munoz is Chairman of the Board of Hybrigenics, a board member of Valneva
SE and adviser to Kurma Biofund.


Mike_bw_background_100x100.jpg

Michael J. Owen

Board member
Elected to the Board in 2012 and regarded as an independent board member.

Qualifications
Ph.D. in Biochemistry from Cambridge University and BA in Biochemistry from Oxford University.

Competencies
Michael J. Owen is a co-founder and former CSO of Kymab Ltd. Before joining
Kymab, he held several leading positions at GlaxoSmithKline, latterly as SVP and
head of biopharmaceuticals research. Prior to joining GSK in 2001, he headed the
Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years' research experience with a focus on the immune system.

Michael J. Owen is board member of Blink Biomedical SAS, Ossianix, Inc., Avacta
Group plc, ReNeuron Group. Plc and GammaDelta Therapeutics. He is also
adviser to Kymab Ltd and CRT Pioneer Fund LP.


ZP_140424_057_web.jpg

Jens Peter Stenvang

Employee-elected board member
Elected to the Board in 2014.

Qualifications
Laboratory Technician (Biology). Jens Peter
Stenvang is a senior application specialist and has worked on cancer and diabetes research at leading universities, including UC Berkeley, California. Before joining Zealand in October 2010, Jens Peter Stenvang worked for Dako and Beckman Coulter in global flow cytometry support.


HHB_100x100_web.jpg

Hanne Heidenheim Bak

Employee-elected board member
Elected to the Board in 2012-2014 and re-elected in 2016.

Qualifications
MS in Pharmacy from the Danish University of Pharmaceutical Sciences. Hanne H. Bak is Senior Project Director and R&D Operations Manager
and has worked as Project Leader of late-phase development programs at H. Lundbeck A/S, followed by a position as Executive Director at the Lundbeck Institute.


RJU_100x100_web.jpg

Rasmus Just

Employee-elected board member
Elected to the Board in 2016.

Qualifications
MS in Biology from the University of Copenhagen, an executive MBA from AVT Business School (Copenhagen) and a PhD in Molecular Pharmacology from University of Copenhagen.
Rasmus Just is Director of Business Development and Innovation Sourcing and has previously held positions as Principal Scientist, Head of Cardiometabolic Innovation and been responsible for the collaboration
with Boehringer Ingelheim GmbH. Rasmus Just is an executive director of Vjack Holding IVS and was previously executive director of Sea Longevity ApS and Vitaminpack IVS.